日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Triglyceride glucose index-a body shape index (TyG-ABSI) outperforms traditional obesity indices in predicting all-cause and cardiovascular mortality in metabolic-dysfunction associated steatotic liver disease: the mediating role of biological aging

甘油三酯葡萄糖指数-体型指数(TyG-ABSI)在预测代谢功能障碍相关脂肪肝疾病患者的全因死亡率和心血管死亡率方面优于传统的肥胖指数:生物衰老在其中起着中介作用

Yang, Guodong; He, Wenli; Qiu, Xin; Shen, Shuang; Li, Peishu; Feng, Yifei; Zhang, Jiayuan; Xiang, Bangde

Efficacy and safety of tyrosine kinase inhibitors in advanced hepatocellular carcinoma patients with Child-Pugh A and B cirrhosis: a meta-analysis

酪氨酸激酶抑制剂治疗伴有Child-Pugh A级和B级肝硬化的晚期肝细胞癌患者的疗效和安全性:一项荟萃分析

Liu, Xionglin; Li, Jindu; Li, MinJun; Xiang, Bangde

Update on the clinical features, treatment and histogenesis of combined hepatocellular-cholangiocarcinoma.

肝细胞癌-胆管癌混合型的临床特征、治疗和组织发生学研究进展。

Hu Junwen, Chen Jiahao, Yang Chenglei, Qi Yapeng, Zhang Jie, Song Rui, Zhong Jianhong, Xiang Bangde

Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)

中国肝细胞癌全程管理专家共识(2023版)

Yang, Yu; Sun, Juxian; Cai, Jianqiang; Chen, Minshan; Dai, Chaoliu; Wen, Tianfu; Xia, Jinglin; Ying, Mingang; Zhang, Zhiwei; Zhang, Xuewen; Fang, Chihua; Shen, Feng; An, Ping; Cai, Qingxian; Cao, Jingyu; Zeng, Zhen; Chen, Gang; Chen, Juan; Chen, Ping; Chen, Yongshun; Shan, Yunfeng; Dang, Shuangsuo; Guo, Wei-Xing; He, Jiefeng; Hu, Heping; Huang, Bin; Jia, Weidong; Jiang, Kexiang; Jin, Yan; Jin, Yongdong; Jin, Yun; Li, Gong; Liang, Yun; Liu, Enyu; Liu, Hao; Peng, Wei; Peng, Zhenwei; Peng, Zhiyi; Qian, Yeben; Ren, Wanhua; Shi, Jie; Song, Yusheng; Tao, Min; Tie, Jun; Wan, Xueying; Wang, Bin; Wang, Jin; Wang, Kai; Wang, Kang; Wang, Xin; Wei, Wenjing; Wu, Fei-Xiang; Xiang, Bangde; Xie, Lin; Xu, Jianming; Yan, Mao-Lin; Ye, Yufu; Yue, Jinbo; Zhang, Xiaoxun; Zhang, Yu; Zhang, Aibin; Zhao, Haitao; Zhao, Weifeng; Zheng, Xin; Zhou, Hongkun; Zhou, Huabang; Zhou, Jun; Zhou, Xinmin; Cheng, Shu-Qun; Li, Qiu

China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)

中国肝癌诊疗指南(2024版)

Zhou, Jian; Sun, Huichuan; Wang, Zheng; Cong, Wenming; Zeng, Mengsu; Zhou, Weiping; Liu, Lianxin; Wen, Tianfu; Kuang, Ming; Zhang, Bixiang; Tao, Kaishan; Han, Guohong; Yan, Zhiping; Wang, Maoqiang; Liu, Ruibao; Guo, Jinhe; Zeng, Zhaochong; Liang, Ping; Ren, Zhenggang; Hou, Jinlin; Zhang, Yanqiao; Liu, Xiufeng; Pan, Hongming; Bi, Feng; Liang, Changhong; Chen, Min; Yan, Fuhua; Xu, Huixiong; Xie, Xiaoyan; Ju, Shenghong; Ji, Yuan; Yun, Jingping; Li, Zengshan; Bai, Xueli; Cai, Dingfang; Chen, Weixia; Chen, Yajin; Chen, Yongjun; Cheng, Wenwu; Cheng, Shuqun; Dai, Zhi; Dai, Chaoliu; Gao, Qiang; Guo, Rongping; Guo, Wengzhi; Guo, Yabing; Hua, Baojin; Huang, Xiaowu; Jiang, Hanyu; Jia, Weidong; Li, Qiu; Li, Tao; Li, Xiangcheng; Li, Xun; Li, Yaming; Li, Yexiong; Liang, Jun; Liang, Xiao; Ling, Changquan; Liu, Hui; Liu, Tianshu; Lu, Shichun; Lv, Guoyue; Mao, Yilei; Meng, Zhiqiang; Peng, Tao; Ren, Weixin; Shi, Guoming; Shi, Hongcheng; Shi, Ming; Song, Tianqiang; Tan, Guang; Wang, Jianhua; Wang, Kui; Wang, Lu; Wang, Wentao; Wang, Xiaoying; Wang, Zhiming; Xiang, Bangde; Xia, Jun; Xing, Baocai; Xu, Jianming; Xu, Jun; Yang, Jianyong; Yang, Xinrong; Yang, Yefa; Yang, Yunke; Yao, Xiaohong; Yin, Zhenyu; Yuan, Zhengang; Zeng, Yongyi; Zeng, Yong; Zhang, Boheng; Zhang, Leida; Zhang, Shuijun; Zhang, Ti; Zhang, Zhiwei; Zhao, Ming; Zhao, Yongfu; Zheng, Honggang; Zhou, Ledu; Zhu, Jiye; Zhu, Kangshun; Shi, Yinghong; Liu, Rong; Zhang, Lan; Xiao, Yongsheng; Yang, Chun; Wu, Zhifeng; Ding, Zhengbin; Zhu, Xiaodong; Tang, Zheng; Huang, Xiaoyong; Han, Hong; Wu, Hong; Chen, Minshan; Wang, Weilin; Li, Qiang; Cai, Jianqiang; Shen, Feng; Cai, Xiujun; Qin, Shukui; Teng, Gaojun; Fan, Jia

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study

比较乐伐替尼与贝伐单抗联合免疫检查点抑制剂和介入三联疗法治疗中国晚期肝细胞癌的疗效:CLEAP 2302 研究

Pan, Zhaolong; Liu, Dongming; Cao, Junbo; Fu, Linlin; Zhang, Xihao; Zhu, Xiaodong; Pan, Yangxun; Liu, Jianwei; Han, Chuangye; Jin, Renan; Shen, Shunli; Zhang, Xiaoyun; Liu, Hongzhi; Yang, Xiaobo; Hu, Kuan; Shi, Xiaoyi; Wang, Dongxu; Zhao, Yang; Zhong, Jianhong; Xiang, Bangde; Gu, Shanzhi; Li, Tao; Zhang, Shuijun; Zhou, Ledu; Zhao, Haitao; Zeng, Yongyi; Wen, Tianfu; Kuang, Ming; Liang, Xiao; Peng, Tao; Wang, Kui; Xu, Li; Li, Huikai; Song, Tianqiang; Sun, Huichuan; Zhang, Wei

Comprehensive strategies for management of postoperative hyper-progression recurrence (HPR) of hepatocellular carcinoma: a 12-year large sample multi-center study

肝细胞癌术后超进展复发(HPR)的综合管理策略:一项为期12年的大样本多中心研究

Qi, Lunan; Xu, Jingxuan; Chen, Yuanyuan; Lu, Zhan; Zhou, Min; Huang, Yingwu; Ling, Yongchi; Huang, Hai; Peng, Yuchong; Peng, Tao; Xiang, Bangde; Ma, Liang

Application and prospect analysis of chimeric antigen receptor T-cell therapy in hepatocellular carcinoma treatment: a systematic review and meta-analysis

嵌合抗原受体T细胞疗法在肝细胞癌治疗中的应用及前景分析:系统评价和荟萃分析

Wu, Sichang; Gan, Xinli; Huang, Shuxin; Zhong, Yujun; Wu, Jialin; Yang, Haojie; Xiang, Bangde

Adherence to the planetary health diet index and metabolic dysfunction-associated steatotic liver disease: a cross-sectional study

遵循行星健康饮食指数与代谢功能障碍相关脂肪肝疾病:一项横断面研究

Qiu, Xin; Shen, Shuang; Jiang, Nizhen; Lu, Donghong; Feng, Yifei; Yang, Guodong; Xiang, Bangde

Pan-Immune-Inflammation Value as a Prognostic Biomarker for Hepatocellular Carcinoma Patients Undergoing Hepatectomy

泛免疫炎症值作为肝细胞癌患者肝切除术的预后生物标志物

Fu, Hongyuan; Wang, Yubo; Xiang, Bangde